Jose Fernando Moura, Clinical Oncologist at Hospital Israelita Albert Einstein, shared on X:
“Evolving mEGFR 2+ L therapy.
Two trials, two different ADCs.
Izalontamab-brengitecan bi-specific (HER3xEGFR), DAR 8 Ruzaltatug-rezetecan (HER3), DAR 4.”
You can also read:
PEARLS/KEYNOTE-091: Long-Term Outcomes With Adjuvant Pembrolizumab in NSCLC
